Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 1,490,029, a decrease of 38.2% compared to RMB 2,409,916 in 2024[3] - Gross profit for the year was RMB 266,864, down 33.1% from RMB 399,202 in the previous year[3] - The company reported a loss from continuing operations of RMB 69,173, compared to a profit of RMB 902,977 in 2024, representing a significant decline[4] - Basic and diluted loss per share for continuing operations was RMB 3.22, compared to earnings of RMB 39.50 per share in 2024[4] - Total comprehensive loss for the year was RMB 69,762, compared to a comprehensive income of RMB 894,139 in the previous year[5] - The adjusted loss before tax for the continuing operations was RMB 51,819 thousand, with segment losses of RMB 32,171 thousand[22] - The company reported a net profit before tax of RMB 929,643,000, with a significant increase in unallocated income and expenses amounting to RMB 30,042,000[24] - The net loss attributable to owners of the company was RMB 75,030,000 in 2025, compared to a profit of RMB 921,078,000 in 2024[47] Assets and Liabilities - Non-current assets decreased to RMB 270,927 from RMB 343,983 in 2024, reflecting a decline of 21.2%[6] - Current assets decreased to RMB 923,305 from RMB 1,086,099, a reduction of 15.0%[6] - Total liabilities decreased to RMB 786,502 from RMB 921,841, indicating a reduction of 14.7%[7] - The company's equity attributable to owners decreased to RMB 378,100 from RMB 461,599, a decline of 18.0%[7] - Total assets amounted to RMB 1,194,232 thousand, with segment assets of RMB 1,127,288 thousand[22] - Total liabilities were RMB 786,502 thousand, with segment liabilities of RMB 762,672 thousand[22] Cash Flow and Expenditures - Cash and cash equivalents increased significantly to RMB 234,359 from RMB 93,765, showing a growth of 150.5%[6] - Capital expenditures for the year were RMB 8,903 thousand, including investments in property, plant, and equipment[23] - Capital expenditures for the year totaled RMB 39,173,000, which includes investments in property, plant, and equipment[25] - The total financial costs decreased to RMB 10,916,000 in 2025 from RMB 30,162,000 in 2024[39] Revenue Segmentation - Total revenue for the year ended December 31, 2025, was RMB 1,490,029 thousand, with external sales of RMB 168,362 thousand from imaging printing products and RMB 1,321,667 thousand from medical products and equipment[22] - The medical business, which accounts for 88.7% of total revenue, reported a revenue of RMB 1,321.7 million, down 39.3% from RMB 2,176.2 million[83] - Non-medical business revenue fell by 27.9% to RMB 168.4 million, with a gross profit margin decline of 1.9 percentage points to 15.6%[86] Impairment and Provisions - The provision for trade receivables impairment decreased to RMB 52,758,000 in 2025 from RMB 64,084,000 in 2024[49] - The company recorded a net impairment loss provision of RMB 9,861,000 for financial assets measured at amortized cost in 2025, compared to a reversal of RMB 603,000 in 2024[55] - The impairment provision for loans to the business partner increased to RMB 48,576,000 as of December 31, 2025, up from RMB 30,720,000 in 2024[57] Market and Strategic Initiatives - The Chinese medical health industry is projected to reach approximately RMB 12.4 trillion by 2025, with the medical device market expected to reach RMB 1.22 trillion[66] - The IVD market is expected to exceed RMB 140 billion by 2025, driven by demand for precision medicine and technological innovations[66] - The company aims to expand its market share and become a leading IVD product distributor in China, focusing on precision oncology and advanced molecular diagnostics[64] - The company continues to expand its overseas market, focusing on its own brands "Yes!Star" and "Yestar Smart," particularly in medical imaging products, achieving record high overseas revenue in 2025[67] Corporate Governance and Compliance - The company has received confirmation from its controlling shareholders regarding compliance with non-competition commitments during the year[110] - The company has adopted the standard code of conduct for securities trading by directors and has confirmed compliance throughout the year[111] Future Outlook - The company is currently evaluating the impact of new international financial reporting standards that are expected to come into effect in 2026 and 2027[16] - The company is analyzing the new requirements introduced by IFRS 18, which replaces IAS 1, to assess its impact on financial statement presentation and disclosures[18] - The company plans to strengthen its overseas market expansion, particularly in Vietnam, the Middle East, Africa, and other Southeast Asian markets[105]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Yestar Healthcare Holdings Company Limited 巨星醫療控股有限公司 （於開曼群島註冊成立的有限公司） 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東及潛在投資者，基於對本集 團截至二零二五年十二月三十一日止年度（「二零二五財政年度」）最新未經審核管理 賬目及董事會現時可獲得的資料作出的初步審閱，相比本集團於截至二零二四年十 二月三十一日止年度（「二零二四財政年度」）的綜合純利約人民幣903.5百萬元，本 集團預期二零二五財政年度錄得本集團綜合虧損淨額不少於人民幣65百萬元。 預期本集團於二零二五財政年度由純利扭盈為虧至虧損淨額，主要源於以下各項： （股份代號：2393） 公告 盈利警告 本公告由巨星醫療控股有限公司（「本公司」，連同其附屬公司統稱為「本集團」）根據 香港聯合交易所有限公司證券上市規則第13.09條及香港法例第571章證券及期貨條 例第XI ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Yestar Healthcare Holdings Company Limited 巨星醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2393） 公告 盈利警告 本公告由巨星醫療控股有限公司（「本公司」，連同其附屬公司統稱為「本集團」）根據 香港聯合交易所有限公司證券上市規則第13.09條及香港法例第571章證券及期貨條 例第XIVA部的內幕消息條文發出。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東及潛在投資者，基於對本集 團截至二零二五年十二月三十一日止年度（「二零二五財政年度」）最新未經審核管理 賬目及董事會現時可獲得的資料作出的初步審閱，相比本集團於截至二零二四年十 二月三十一日止年度（「二零二四財政年度」）的綜合純利約人民幣903.5百萬元，本 集團預期二零二五財政年度錄得本集團綜合虧損淨額不少於人民幣65百萬元。 預期本集團於二零二五財政年度由純利扭盈為虧至虧 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 董事會會議日期 巨星醫療控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本公司將 於二零二六年三月二十七日（星期五）舉行董事會會議，藉以（其中包括）考慮及批准 本公司及其附屬公司截至二零二五年十二月三十一日止年度的全年業績，以及建議 派付末期股息（如有）。 承董事會命 Yestar Healthcare Holdings Company Limited 巨星醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2393） 於本公告日期，執行董事為王春來先生、喬金榮先生及廖長香女士；非執行董事為 何震發先生；而獨立非執行董事為曾勁松先生、趙自偉先生及鄺向凡先生。 巨星醫療控股有限公司 行政總裁兼執行董事 王春來 二零二六年三月十六日 ...

補充公告 茲提述巨星醫療控股有限公司（「本公司」，連同其附屬公司統稱為「本集團」）日期為 二零二六年二月六日的公告，內容關於有關該等收購事項的須予披露交易（「該公 告」）。除非另有界定，否則本補充公告所用的專有詞彙應具有該公告所界定的相同 涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Yestar Healthcare Holdings Company Limited 巨星醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2393） 有關收購高性能材料生產設備的 須予披露交易的 本公司董事（「董事」）會（「董事會」）謹此向本公司股東及潛在投資者提供有關該等收 購事項的進一步資料。 代價基準 誠如該公告所披露，根據第一份協議及第二份協議買方應付的代價乃按一般商務條 款訂立，並於主要分別參考生產設備及主設備的市價後經公平磋商協定。 根據獨立估值師北京贏越資產評估有限公司（「估值師」）對生產設備及主設備（「設 備」）進行的估值（「估 ...

致：香港交易及結算所有限公司 公司名稱: 巨星醫療控股有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02393 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.025 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 4,000,000,000 | HKD | | 0.025 | HKD | | 100,000,000 | 本月底法定/註冊股本總額： HKD 100,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截 ...

Group 1 - The core viewpoint of the article is that Giant Medical Holdings (02393.HK) has entered into two agreements for the acquisition of production equipment, totaling $7.2 million [1] Group 2 - The first acquisition agreement, signed on October 21, 2025, involves the purchase of production equipment for a total consideration of $1.85 million [1] - The second acquisition agreement, signed on February 6, 2026, involves the purchase of main equipment for a total consideration of $5.35 million [1] - The equipment acquired in the first agreement includes pre-crosslinking mixing systems, coating solution mixing systems, coating solution delivery systems, module evaluation systems, and other accessories [1] - The equipment acquired in the second agreement includes high-performance material production and testing equipment, such as membrane coating production line systems, evaluation systems, product packaging systems, plasma treatment systems, and related consumables and materials [1]

Group 1 - The company, Giant Star Medical Holdings (02393), announced the acquisition of production equipment for a total cost of $1.85 million and $5.35 million for main equipment, totaling $7.2 million for both acquisitions [1][2] - The acquisitions are aimed at transforming the company into a high-performance materials engineering company and manufacturer, aligning with its current business strategy [2] - The high-performance materials industry involves designing, constructing, and commercializing materials that outperform traditional counterparts by at least an order of magnitude [1] Group 2 - The acquired production and main equipment are crucial for research and development, enabling the company to conduct research, testing, evaluation, and ultimately production of high-performance membrane materials [2] - The company believes that the acquisitions will diversify its business segments through synergies in material research and development, leveraging experience gained from fine production of S2 film cameras over the past two years [2]

Group 1 - The company, Giant Medical Holdings (02393), announced the acquisition of production equipment for a total consideration of $1.85 million and $5.35 million for the main equipment, totaling $7.2 million for both acquisitions [1][2] - The acquisitions are aimed at transforming the company into a high-performance materials engineering company and manufacturer, aligning with its current business strategy [2] - The high-performance materials industry is part of the manufacturing sector, focusing on designing, constructing, and commercializing materials that outperform traditional counterparts by at least an order of magnitude [1][2] Group 2 - The acquired production and main equipment are crucial for research and development, enabling the company to conduct research, testing, evaluation, and ultimately the production of high-performance membrane materials [2] - The board believes that the acquisitions will diversify the company's business segments through synergies in material research and development, leveraging the experience gained from fine production of S2 film cameras over the past two years [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Yestar Healthcare Holdings Company Limited 巨星醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2393） 第二收購事項 由於涉及第二收購事項的最高適用百分比率（定義見上市規則）獨立計算高於5% 但低於25%，故根據上市規則第十四章，第二收購事項構成須予披露交易，須遵 守通知及公告規定。 – 1 – 此外，由於第一份協議及第二份協議均由買方與賣方於12個月期間內訂立，故根 據上市規則第14.22條及第14.23條，據此擬進行的交易應合併計算。由於涉及第 二收購事項的最高適用百分比率（定義見上市規則）與第一收購事項合併計算高於 5%但低於25%，故根據上市規則第十四章，該等收購事項構成須予披露交易， 須遵守通知及公告規定。 有關 收購高性能材料生產設備的 須予披露交易 收購設備 於二零二五年十月二十一日，買方（本公司的間接全資附屬公司）與賣方就收購 ...